Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Niccoli

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Open Access Rheumatology : Research and Reviews|December 4, 2009
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisFabrizio Cantini, Carlotta Nannini, Laura Niccoli
The Journal of Rheumatology. Supplement|May 3, 2014
Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillanceFabrizio Cantini, Laura Niccoli, Delia Goletti
The Journal of Rheumatology. Supplement|May 3, 2014
Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registriesFabrizio Cantini, Laura Niccoli, Delia Goletti
The Israel Medical Association Journal : IMAJ|March 10, 2020
The Nocebo Effect in Rheumatology: An Unexplored IssueFabrizio Cantini, Laura Niccoli, Giulia Franchi, et al.
International Journal of Rheumatic Diseases|February 14, 2012
Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring anti-TNFα drugs and therapy-induced changesLaura Niccoli, Carlotta Nannini, Emanuele Cassarà, et al.
European Journal of Rheumatology|January 9, 2018
Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originatorFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Biologics : Targets & Therapy|January 16, 2013
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up studyFabrizio Cantini, Laura Niccoli, Emanuele Cassarà, et al.
The Journal of Rheumatology. Supplement|November 3, 2015
Uveitis in Spondyloarthritis: An OverviewFabrizio Cantini, Carlotta Nannini, Emanuele Cassarà, et al.
Drugs & Aging|March 26, 2008
Diagnosis and treatment of giant cell arteritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|May 9, 2019
Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceFabrizio Cantini, Laura Niccoli, Alessandro Capone, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Open Access Rheumatology : Research and Reviews|December 4, 2009
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisFabrizio Cantini, Carlotta Nannini, Laura Niccoli
The Journal of Rheumatology. Supplement|May 3, 2014
Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillanceFabrizio Cantini, Laura Niccoli, Delia Goletti
The Journal of Rheumatology. Supplement|May 3, 2014
Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registriesFabrizio Cantini, Laura Niccoli, Delia Goletti
The Israel Medical Association Journal : IMAJ|March 10, 2020
The Nocebo Effect in Rheumatology: An Unexplored IssueFabrizio Cantini, Laura Niccoli, Giulia Franchi, et al.
International Journal of Rheumatic Diseases|February 14, 2012
Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring anti-TNFα drugs and therapy-induced changesLaura Niccoli, Carlotta Nannini, Emanuele Cassarà, et al.
European Journal of Rheumatology|January 9, 2018
Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originatorFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Biologics : Targets & Therapy|January 16, 2013
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up studyFabrizio Cantini, Laura Niccoli, Emanuele Cassarà, et al.
The Journal of Rheumatology. Supplement|November 3, 2015
Uveitis in Spondyloarthritis: An OverviewFabrizio Cantini, Carlotta Nannini, Emanuele Cassarà, et al.
Drugs & Aging|March 26, 2008
Diagnosis and treatment of giant cell arteritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Expert Opinion on Drug Safety|May 9, 2019
Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practiceFabrizio Cantini, Laura Niccoli, Alessandro Capone, et al.
Pageof 5